Gamal A. Elfar*†, Mohamed A. Ebrahim‡, Nehal M. Elsherbiny*, Laila A. Eissa*
Oncology Research, Vol.25, No.4, pp. 641-650, 2017, DOI:10.3727/096504016X14768398678750
Abstract Osteoprotegerin (OPG) is a robust antiresorptive molecule that acts as a decoy receptor for the receptor activator of nuclear factor kB ligand (RANKL), the mediator of osteoclastogenesis. This study was designed to
explore the possible role of serum OPG and RANKL in detecting bone metastasis in breast cancer and its interaction with clinicopathologic parameters. Serum levels of RANKL and OPG were estimated in 44 metastatic
and 36 nonmetastatic breast cancer patients using ELISA kits. Serum OPG levels were significantly reduced in
patients with bone metastasis and correlated negatively with the number of bone lesions and… More >
Login
Register
